Becton Dickinson & Company
Exchange: NYSESector: HealthcareIndustry: Medical Instruments & Supplies
Becton Dickinson and Co, formerly Becton Dickinson & Co is a global medical technology company engaged in the development, manufacture and sale of medical devices, instrument systems and reagents used by healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. The Company' s operations consist of three business segments: BD Medical, BD Diagnostics and BD Biosciences. On February 9, 2012, the Company acquired a 100% interest in KIESTRA Lab Automation BV. On August 24, 2012, the Company acquired a 100% interest in Sirigen Group Limited. On October 31, 2012, the Company sold its BD Biosciences -Discovery Labware unit. In December 2012, the Company acquired Safety Syringes, Inc. Effective March 12, 2013, the Company acquired Cato Software Solutions GmbH.
Did you know?
Profit margin stands at 8.0%.
Current Price
$154.51
-1.17%GoodMoat Value
$146.37
5.3% overvaluedProfile
Valuation (TTM)
Market Cap$44.10B
P/E25.10
EV$63.09B
P/B1.74
Shares Out285.42M
P/Sales2.01
Revenue$21.92B
EV/EBITDA12.40
Becton Dickinson & Company (BDX) Stock Analysis
GoodMoat Analysis
Becton Dickinson is a leading medical technology company with a durable moat built on switching costs and regulatory barriers, but it currently presents an unfavourable valuation for a value investor. The stock trades above its estimated fair value, and its low revenue growth and quality metrics fail to meet the framework's gate for further analysis.
Read full analysis
Becton Dickinson (BDX) is a global leader in medical technology, manufacturing and selling medical devices, instrument systems, and reagents. Applying the GoodMoat framework, the company demonstrates a potentially durable competitive advantage. Its moat is anchored in high switching costs, as its devices and software are mission-critical in healthcare settings with significant integration and retraining costs, and regulatory barriers, where its portfolio of FDA-approved products and complex manufacturing processes create high entry hurdles. However, the Moat Score would likely be moderate, as other criteria like network effects or proprietary data are less applicable. The company's quality indicators are mixed. While it generates a stable free cash flow yield of 5.9% and pays a dividend, key metrics are weak: revenue growth is low at 1.6% YoY, ROE is 6.9% (well below the 15-20% high-quality threshold), and profit margins are modest at 8.0%. This profile does not meet the framework's 'Proceed' gate, which requires a Moat Score ≥5 and predominantly 'Strong' quality ratings. On valuation, the current price of $158.27 is above the GoodMoat Target of $146.37, indicating no margin of safety. The P/E of 25.7x is high for a company with single-digit growth and returns. For a value investor, BDX is a high-quality business in a defensive sector, but its current price and fundamental performance make it an unfavourable candidate for further investigation without a more attractive entry point. Analysis based on data as of 2024-05-15.
Market Cap$44.10B
Current Price$154.51
P/E Ratio25.10
Forward P/E—
PEG Ratio0.91
EPS$5.82
Book Value$88.96
P/B Ratio1.74
BDX Financial Charts
FCF vs CAPEX
FCFCAPEX
Forward estimates use 2.0% FCF growth (CAGR)
Cash vs Debt
Net Debt: 18.3B
Revenue
17.3B
FY19
16.1B
FY20
19.1B
FY21
18.9B
FY22
19.4B
FY23
20.2B
FY24
21.8B
FY25
Net Income
1.2B
FY19
874M
FY20
2.1B
FY21
1.8B
FY22
1.5B
FY23
1.7B
FY24
1.7B
FY25
BDX 52-Week Range
$126.84
$184.21
50-Day MA: $165.18200-Day MA: $150.94
Did you know?
Trading 5% above its estimated fair value of $146.37.
Becton Dickinson & Company (BDX) Financial Summary
Becton Dickinson & Company (BDX) is a Healthcare company in the Medical Instruments & Supplies industry, listed on NYSE. The stock currently trades at $154.51 with a market capitalization of $44.10B.
Key valuation metrics include a P/E ratio of 25.10, price-to-book ratio of 1.74, and EPS of $5.82. The company reports a profit margin of 8.0% and return on equity of 6.9%.
BDX Key Financial Metrics
| Metric | Value |
|---|---|
| Market Cap | $44.10B |
| P/E Ratio | 25.10 |
| EPS | $5.82 |
| P/B Ratio | 1.74 |
| P/S Ratio | 2.01 |
| EV/EBITDA | 12.40 |
| Dividend Yield | 2.71% |
| Profit Margin | 8.0% |
| Return on Equity | 6.9% |
| Debt/Equity | 0.76 |
BDX Revenue & Earnings History
| Year | Revenue | Net Income |
|---|---|---|
| FY19 | $17.29B | $1.23B |
| FY20 | $16.07B | $874.00M |
| FY21 | $19.13B | $2.09B |
| FY22 | $18.87B | $1.78B |
| FY23 | $19.37B | $1.48B |
| FY24 | $20.18B | $1.71B |
| FY25 | $21.84B | $1.68B |
Becton Dickinson & Company (BDX) Valuation
Based on GoodMoat's DCF model, Becton Dickinson & Company has a fair value estimate of $146.37. At the current price of $154.51, the stock appears 5.6% overvalued relative to our intrinsic value estimate.
BDX Quality Indicators
Becton Dickinson & Company maintains a profit margin of 8.0% and an operating margin of 11.8%. Return on equity stands at 6.9%. The current ratio is 1.11. Debt-to-equity ratio is 0.76.
About Becton Dickinson & Company
Becton Dickinson and Co, formerly Becton Dickinson & Co is a global medical technology company engaged in the development, manufacture and sale of medical devices, instrument systems and reagents used by healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. The Company' s operations consist of three business segments: BD Medical, BD Diagnostics and BD Biosciences. On February 9, 2012, the Company acquired a 100% interest in KIESTRA Lab Automation BV. On August 24, 2012, the Company acquired a 100% interest in Sirigen Group Limited. On October 31, 2012, the Company sold its BD Biosciences -Discovery Labware unit. In December 2012, the Company acquired Safety Syringes, Inc. Effective March 12, 2013, the Company acquired Cato Software Solutions GmbH.
BDX Free Cash Flow
Becton Dickinson & Company generated $2.67B in trailing twelve-month free cash flow, representing an FCF yield of 6.05%. This strong FCF yield suggests the company generates substantial cash relative to its market value.
BDX Shares Outstanding
Becton Dickinson & Company has 0.29 billion shares outstanding at a share price of $154.51, giving it a market capitalization of $44.10B.
BDX Recent Insider Trades
Recent insider transactions at Becton Dickinson & Company include:
| Insider | Type | Shares | Value |
|---|---|---|---|
| Feld Michael (EVP, Chief Revenue Officer) | SELL | 75 | $11762.25 |
| Feld Michael (EVP, Chief Revenue Officer) | SELL | 75 | $13638.00 |
| SCOTT BERTRAM L | SELL | 953 | $174027.33 |